For the past 60 years, antibiotic drugs have changed bacterial infections from the life-threatening scourges they once were into eminently treatable conditions. However, the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to traditional agents. As a result, pharmaceutical companies are taking a second look at the antibiotic market, after more than two decades of relative complacency.
In addition to the scientific and technical challenges of new antibiotic development, there are significant business challenges, as well. The 2004 market for antibacterials actually posted a decline over 2003 and generic competition continues to threaten the anti-infective franchises of major manufacturers. Development cost for new anti-infectives have been shown to be higher than other therapeutic classes and political and economic pressures particular to anti-infective classes make recovering these costs challenging.
In this study, Kalorama Information segments the market for antibacterial medication into seven general categories based on drug class:
- other misc. antibiotics
For each segment, the report provides market size, growth, and share. The base year for data was 2004. Historical data are provided for the years 2002 and 2003, with forecast data provided for 2005 through 2009, based on probability of approval and sales of products in late stage development, product marketing, and demographic trends. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009 and 2002-2009 periods for each industry segment covered. Market shares by supplier, by infection type, and by top products are provided for the year 2004. Regional breakdowns in each segment are provided for the United States, Europe, Japan, and Rest of World for the entire forecast period. All market data are provided at the manufacturers’ level in constant U.S. dollars.
In addition to market data, the report includes statistical information on bacterial infections by type worldwide, with special emphasis on the U.S. market. The market segments provide an overview, description of products on the market, and a description of products in development. The report also includes current issues and trends affecting the industry, including:
- Antibiotic drug development and costs
- Drug resistance and interactions
- Antibiotic cycling
- Incentives to develop antibiotics
- Antibiotic use in agriculture
- Antibiotic education
- Special usage issues in pediatric and geriatric populations
- Immunocompromised individuals and resistance
- Antibiotics and atherosclerosis
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and e-mail correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.